Vor Bio reinvents itself as an autoimmune biotech

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It's a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives.

Editor's Pick

Top Story Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It's a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives. Sponsored Break the Cycle of Bad Provider Data—Download the Guide Presented by ProviderTrust It's time to treat provider data as the dynamic, strategic asset it truly is. Download our new guide to discover how interoperability can solve your provider data challenges. You'll learn: Common obstacles healthcare leaders face Strategies to improve data integrity and transparency How to build a roadmap for real, lasting change Let's break down the silos—starting today. Apply to Pitch at INVEST Digital Health 2025 in Dallas Are you redefining healthcare operations with AI? We're looking for the next wave of digital health startups using artificial intelligence to transform the day-to-day work of providers. If your solution streamlines diagnosis, clinical documentation, scheduling, or patient engagement, this is your moment to shine. Click here to learn more and apply.

Featured News

Certify Raises $40M To Advance Healthcare Provider Data Infrastructure Certify's $40 million round was led by Transformation Capital, and included support from General Catalyst, Upfront Ventures and SemperVirens.  From Burnout to Breakthrough: Reinventing Pediatric Care for the Next Generation There is no singular cause to pediatrician burnout. Rather, it's a web of interconnected issues, compounded and feeding upon each other. And if we want to truly support pediatricians and the children they care for, we need to stop treating symptoms and start untangling the root causes.  Beyond Technology: Aligning AI Tools with Systemic Change in Healthcare The widespread investment in AI furthers economists' optimism about a "roaring 20's" of worker productivity on the horizon. However, this will not take place in health care without accompanying systemic and organizational actions that rethink what we financially incentivize, how we integrate new technologies, how we shift tasks, and how we prepare the workforce.

Video   Why Capping Hospital Rate Increases Doesn't Lower Employer Insurance Premiums At the HMFA Annual Conference in Denver, Rod Hanners, CEO of Keck Medicine of USC, said that efforts to limit hospital rate increases aren't reducing employer insurance premiums, as intended.

Sponsored Navina's AI Copilot Eases the Value-Based Burden, Study Shows Presented by Navina A new independent study from Phyx Primary Care's Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices. Learn More

Resources

MedCity Pivot: How Veradigm Aims to Close the Information Gap Megan Zakrewsky, vice president of product at Veradigm talks about how the company is utilizing tech among providers, payers and patients. Watch now!

MedCity News • PO Box 901 • New York, NY unsubscribe